You are here:
25 February 2021 / news

New CSSF interactive digital portal: e-Prospectus

The CSSF has built a new digital portal (e-Prospectus) where issuers will, as of 1 March 2021, be able to submit and follow their application requests under the Prospectus Regulation and the Luxembourg Prospectus Law. Access to the e-Prospectus platform will require the possession of a LuxTrust certificate.

Security icons and laptop typing - New CSSF e-Prospectus

The CSSF is responsible for the application of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, as amended (Prospectus Regulation) and the law of 16 July 2019 on prospectuses for securities (Prospectus Law), which implements certain provisions of the Prospectus Regulation and provides for requirements covering the national prospectus regime.

The Prospectus Regulation led to several changes to these processes. To respond to these changes, the CSSF has developed e-Prospectus, an interactive, intuitive and transparent tool which will allow issuers to submit and track applications related to the Prospectus Regulation and the Prospectus Law.

The new digital portal will be available on the CSSF website as of 1 March 2021.

What applications are covered by the e-Prospectus platform?

The e-Prospectus platform will cover:

  • Submissions and follow-up of applications for approval of prospectuses and supplements.
  • Submissions of requests for notification in relation to the above cases.

These operations will need to be carried out through an e-Prospectus account. The CSSF will no longer accept submissions via email, except for Final Terms which will continue to be submitted via the Final Terms Form published on the CSSF website.

Who needs an e-Prospectus account?

  • Depositors will need an e-Prospectus account.
  • Issuers introducing their applications via a law firm/depositor can also create an e-Prospectus account if they possess a LuxTrust certificate.
  • Each person intending to work on the e-Prospectus platform should have his/her own e-Prospectus account (and therefore also his/her certificate).

How do you create and access an e-Prospectus account?

A LuxTrust certificate will be required to create and access an e-Prospectus account. Certificates from LuxTrust guarantee via different products (token, smartcard, mobile app, etc.) the identity and authentication of the person who connects to an online application for performing electronic operations. Both private and professional LuxTrust certificates can be used. Each certificate can only be linked to one e-Prospectus account. Non-residents can also get a LuxTrust certificate and LuxTrust subscriptions are valid for 3 years.

For further information, please consult the CSSF website (e-Prospectus) and CSSF User Guides:

User guide Authentication and Access – CSSF
e-Prospectus – FAQ LuxTrust – CSSF
Prospectus III user guide for submission and follow up on an approval request
Prospectus III user guide for submission and follow up on an approval request (Data Fields)
Prospectus III user guide for submission and follow up on an approval request (Notification)



EC published its long-waited Q&A clarifying the scope of SFDR disclosures for AIFMs

EC Q&A on the scope of SFDR disclosures for AIFMs

the EC clarified that both non-EU AIFMs and sub-threshold AIFMs must ensure compliance with the disclosure obligations of the SFDR. read more
Coronavirus - Belgian measures for businesses

Coronavirus | Belgian measures for businesses

Since 3 March 2020 different authorities (EU, national, local) took measures in Belgium to reduce the spreading of the COVID-19 virus. In order to overcome the... read more
Loyens & Loeff team successfully advised the Pierre & Vacances group in its restructuring

Loyens & Loeff team advised the Pierre & Vacances group

On 24 June 2021, the restructuring of the Pierre & Vacances group was completed. read more
Stay informed

Don't miss out. Stay up to date about our latest news and events.

Stay informed